COMPANY NEWS & UPDATES
iXCells Biotechnologies Expands CRISPR-Cas9 Cell Products and Genome Engineering Services
Gene Editing Services Deliver Disease Relevant Cell Models to Improve Preclinical Drug Development
May 16, 2023 10:04 AM Eastern Standard Time
SAN DIEGO--(BUSINESS WIRE)--iXCells Biotechnologies (the “Company”), a provider of cell products and drug discovery services to the worldwide academic, biotech and pharmaceutical communities, today announced expansion of its CRISPR-Cas9 product and custom services offering, with special focus on induced pluripotent stem cell (“iPSC”) derived cell models.
iXCells Biotechnologies & FUJIFILM WAKO ANNOUNCE DISTRIBUTION PARTNERSHIP
Continued Global Expansion
March 14, 2023
iXCells Biotechnologies has partnered with Fujifilm WAKO Pure Chemical Corp. to offer high-quality primary cells, cell culture media, and reagents to Japan's life science industry. This collaboration will enable researchers in Japan to access a wide range of primary cell types, including fibroblasts, endothelial cells, epithelial cells, PBMCs, immune cells, muscle cells, neuronal cells, hepatocytes, and stem cells for drug discovery and development.
iXCells Biotechnologies Exhibiting at neuroscience 2022 in san diego
Join us at Neuroscience 2022 conference November 13-16
November 3rd, 2022
The Society for Neuroscience is the world’s largest organization of scientists and physicians devoted to understanding the brain and nervous system.
If you'd like to discuss solutions that accelerate drug discovery workflows with a focus on neurodegenerative / CNS disease models and chat with our team of scientists and commercial staff about our latest products, please visit us on booth 2614.
Stay tuned for more information on posters to be presented by the iXCells neuroscientific experts during the event.
iXCells Biotechnologies Secures Strategic Growth Investment from Great Point Partners
Recapitalization Propels Key Growth Initiatives
September 29th, 2022 10:03 AM Eastern Standard Time
SAN DIEGO--(BUSINESS WIRE) -- iXCells Biotechnologies (“iXCells” or the “Company”), a high growth provider of cell-based products and discovery services to the academic, biotech and pharmaceutical communities worldwide, with special focus on primary and induced pluripotent stem cell (“iPSC”) derived cellular models announces a growth investment from Connecticut-based Great Point Partners (“GPP”), a private investment firm focusing on the healthcare industry.
iXCells Biotechnologies and Life Technologies India Announce Distribution Agreement
Strategic Initiative to drive continued growth.
August 16, 2022
iXCells Biotechnologies a leading cell technology company specializing in preclinical drug discovery solutions, today announced it has entered into a distribution agreement with Life Technologies India Pvt. Ltd.
June 2, 2022
Please join us in person at BIO 2022 meeting June 13 to 16 at the San Diego CA Convention Center. iXCells Biotechnologies USA, Inc. will be participating in the One-On-One Partnering Forum. Schedule meetings with Nianwei Lin, President and Co-Founder, and Wayne Vaz, VP, Corporate Development & Commercial Operations inside or outside the Partnering Forum.
The BIO International Convention attracts 15,000+ biotechnology and pharma leaders for one week of intensive networking to discover new opportunities and promising partnerships. The conference brings together a wide spectrum of life science and application innovators, including drug discovery, biomanufacturing, genomics, nanotechnology, and cell therapy.
May 5, 2022
Please join us at Immunology 2022 meeting May 6th to 10th in Portland, OR at the Oregon Convention Center. The largest annual meeting event worldwide, the AAI annual meeting is where leading researchers come to learn the latest in their field. Visit iXCells Biotechnologies at booth 731 in the Exhibit Hall to see our latest products, services, and advancements!
Mar 23, 2022
We are excited to annoce that we will be attending the Society of Toxicology (SOT) 61st Annual Meeting and ToxExpo from March 27th to March 31st in San Diego, California. Visit us at booth 1921 in the Exhibit Hall to see our latest products, service and advancements!
Feb 10, 2022
A recent publication highlighting our hiPSC-derived motor neurons (iPSC-MN) can mature in vivo after transplanted into rat spinal cord. Significant motor axonal extension after transplantation in the animal models demonstrates that motor neuron replacement therapy could be a promising therapeutic strategy for amyotrophic lateral sclerosis (ALS).
Feb 7, 2022
In this interview with Nianwei Lin, Co-Founder and President of iXCells Biotechnologies, we discuss the company’s product pipeline, innovative drug discovery solutions, CRO services, and its future goals.
Dec 21, 2021
iXCells Biotechnologies, a provider of induced pluripotent stem cells (iPSCs), differentiation services, primary cells, media and reagents for drug discovery and development, today announced key growth initiatives.
